Search Tufts Medicine

Approximately 230,000 women are diagnosed with invasive breast cancer and 60,000 women are diagnosed with ductal carcinoma in situ (DCIS) (breast cancer in the breast milk ducts) annually in the US. Most women choose to be treated with breast conserving surgery (BCS). The goal of BCS is to resect the tumor with a surrounding margin of tissue free of cancer, and to minimize the volume of tissue removed, thereby preserving the overall shape and appearance of the breast.

GO MOMS is a study that tracks maternal blood sugar levels in pregnancy and how the levels may predict the development of gestational diabetes (pregnancy-related high blood sugar) or relate to the size of a baby at birth. As not enough is known about who will get gestational diabetes and because treatment of gestational diabetes in later pregnancy does not make all of the complications go away, learning about the early pregnancy blood sugars may help us learn how to improve prenatal care in the future for healthier families.

Premature infants can get a serious inflammatory condition, called necrotizing enterocolitis (NEC), that damages parts of the intestines. It is the most common cause of illness of the intestinal tract in premature infants in the first few weeks of life. It is a very serious condition that can lead to death in up to half of affected infants. There is no way to predict whether an infant will get NEC, and there are no reliable early warning signals. There is no established preventive treatment for NEC.

In this study, researchers are hoping to improve post-operative pain control and reduce opioid use using a technique called TAP block. A TAP block is a form of pain relief that "blocks" the pain receptors in a person's abdomen and can be performed during minimally invasive hysterectomy. Enrolled participants undergoing minimally invasive hysterectomy will be randomized to three pain control or TAP block options.

Our main goal is to use a special type of microscopic imaging to help detect cervical pre-cancers without the need for labels or dyes. We've been working closely with doctors at Tufts Medical Center for more than ten years and have studied images from over seventy cervical tissue samples taken from humans. We shine a laser on the tissues with two different types of light, and this caused certain molecules in the cells to give off light, which we collected and analyzed. By scanning the tissues in this way, we could make 3D images and measure how the cell structures changed with depth.

This is a study to determine if a video that utilizes a peer to teach self administration of subcutaneous depot medroxyprogesterone is both effective and well accepted by adolescent patients who are already receiving ongoing treatment with depot medroxyprogesterone by a medical provider via an inter muscular injection.  Self administration can be done at home and therefore offers an alternative to traveling to a medical office.

The purpose of this study is to establish a large, international, web based registry, using the Surgical Outcomes System (SOS), to collect baseline characteristics of patients undergoing orthopaedic and sports medicine, arthroscopy, and related surgery, and the subsequent outcomes and costs-effectiveness associated with the surgical procedures. Additionally, baseline and outcome data for non-operative treatment procedures will b collected using the same measures in order to compare to surgical outcomes.

Observational study to evaluate new imaging methods and software of the Topcon prototype OCT instrument for ocular blood flow imaging of patients with different retinal diseases and healthy volunteers.

This is a longitudinal observational study that will look at 300 subjects, 200 with intermediate AMD in at least one eye, or with AMD in one eye, either early or intermediate, and with late AMD (exudative) in the other eye, and 100 subjects with nGA or GA in at least one eye.

The target population is all subjects who are at least 50 years of age and have a clinical diagnosis of non-exudative AMD in at least one eye.

This study is designed to test a potential biomarker to identify NCP patients. A biomarker is a characteristic that is unique to NCP patients and will help to identify them from DED patients so that correct treatment can be provided to them.

• To establish the prevalence of neuropathic corneal pain in patients with ocular surface discomfort.
• To assess the overlap of neuropathic corneal pain with dry eye disease in patients in diseases that are currently thought to be mutually exclusive.
• To establish the prevalence of subtypes of patients with neuropathic corneal pain or with a neuropathic component of dry eye in patients with ocular surface discomfort.

This prospective, single center, randomized, double-masked, parallel comparison, sponsored study seeks to investigate the efficacy of IDI on ameliorating the signs and symptoms of dry eye disease. The study aims to enroll 54 patients (36 Dextenza commercial formulation, 18 Collagen Plug) with DED.

We propose to develop an economic in-office pain tests that may help screen and differentiate patients with neuropathic corneal pain (NCP) that could be used at any ophthalmic office. These five in-office pain tests include response with filter glasses, moisture googles, cold saline, hypertonic saline and topical proparcaine.

Persistent corneal epithelial defect (PCED) is a persistent non-healing corneal defect or wound. KPI-012 is a novel, human bone-marrow derived human mesenchymal stem cell (hMSC) secretome composed of biologically active components, which have been shown in preclinical studies and early clinical trials to facilitate corneal healing. This study will investigate the efficacy and safety of KPI-012 eye drops 4 times daily for 8-weeks for healing of PCED.

To assess the safety and efficacy of oral medication, deucravacitinib (DEUC) at 3 mg twice daily (BID) vs. 6 mg BID vs. the placebo in participants with active Sjögren’s syndrome (SjS).

RGN-259 eye drops compared to placebo eye drops 5 times per day in both eyes for the treatment of Neurotrophic Keratopathy. Percentage of subjects achieving complete healing (defined as 0 mm lesion size) of the Persistent Epithelial Defect (PED) at Visit 5 (Day 29) determined by corneal fluorescein staining captured by corneal photography and analyzed by a central reading center

After completing enrollment in the original DEFENDO Study, patients will be invited to enter the DEFENDO Long-Term Follow-up Study (all standard of care is permitted). Two additional long-term follow-up visits will occur at 18- and 24-months to evaluate long-term clinical outcomes. No study treatment will be provided. Patients will be treated per standard of care as determined by the Investigator and will document topical ophthalmic medications currently being administered at time of study participation.

The study will evaluate the efficacy, safety and pharmacokinetics of faricimab compared with aflibercept in patients with macular edema due to branch retinal vein occlusion (BRVO) up to the primary endpoint at Week 24.

This study is a Phase IV multicenter, open-label (BCVA assessor-masked) study designed to assess the response to treatment with SUSVIMO every 24 weeks in patients with Neovascular Age-Related Macular Degeneration (nAMD) who have been previously treated with anti-VEGF agents other than ranibizumab.

Patients who need vision testing (acuity and fields) will be asked to be tested at home or at the bedside with the ViuALL device. They and their phyysicians will be asked about the advantages and disadvantages of the new device.